Pharmacogenetics โ Conditions Under Which Genetic Information Is Incorporated Into Prescriptions
Why It Matters
Even when the same drug is administered at the same dose, blood concentrations, therapeutic responses, and risks of adverse reactions can vary among individuals. While acquired factors such as age, hepatic and renal function, and concomitant medications play a significant role, genetic differences in drug-metabolizing enzymes, transporters, and target proteins provide predictable information for certain geneโdrug pairs. Pharmacogenetics investigates how to link these variations to prescribing decisions.
The critical scope is not โpredicting all drug responses via genetics.โ For clinical utility, the relationship between specific genotypes and phenotypes must be reproducible, and there must be actionable prescribing alternatives corresponding to those phenotypes. Therefore, while pharmacogenetic results can serve as precise evidence, the applicable drugs and scenarios are limited.
Key Concepts
The laboratory categorizes observed variant combinations into star alleles or haplotypes and infers the metabolic phenotype from the diplotype, which consists of a combination of two haplotypes. For example, within the same gene, normal-function, reduced-function, and nonfunctional alleles may combine, resulting in categories such as normal, intermediate, or poor metabolizers. Because nomenclature and phenotypic rules vary by gene, prescribing information cannot be derived solely from the presence of a variant.
CPIC guidelines do not serve as criteria for selecting individuals for testing; rather, they explain how to utilize genetic results once available. The guidelines review evidence for each geneโdrug pair, providing genotype-to-phenotype conversion, recommendation strength, and potential drug or dose adjustments. Decisions regarding test implementation depend on factors separate from the guidelines, including disease prevalence, turnaround time, cost, and healthcare system considerations.
The Flow of Results Informing Prescribing
In clinical practice, the process involves multiple stages: specimen and assay โ variant/haplotype call โ diplotype โ phenotype โ drug-specific recommendations โ final judgment incorporating patient context. If any single stage is incomplete, the certainty of subsequent stages diminishes. Particularly for loci such as CYP2D6, where copy-number variations and hybrid alleles are common, constructing an accurate diplotype based solely on SNP testing is difficult.
Results must include the genome build, assay scope, allele-definition database, interpretation guidelines, and software version. Forcing a no-call or ambiguous combination into the nearest phenotype can create false confidence that mimics precision medicine but is fundamentally flawed.
Small Example
Consider a scenario in which a drug is converted into an active metabolite by a specific enzyme. Individuals with significantly reduced enzyme function may fail to produce sufficient active metabolite even at the same dose. Conversely, if the enzyme inactivates the drug, reduced function can lead to increased exposure and an elevated risk of adverse reactions. The key point is that the clinical significance can be opposite depending on the direction of metabolism, even among individuals classified as poor metabolizers.
This example illustrates the principle only and does not constitute individualized prescribing advice. Actual recommendations require verification of specific drugs, indications, current guidelines, and labeling information.
Clinical Context Beyond Genetic Information
While the genotype remains largely stable throughout life, observed drug handling capacity (phenotype) can be altered by concomitant medications. Co-administration of enzyme inhibitors may cause individuals with normal genetic function to exhibit a low-functioning phenotype, a phenomenon known as phenoconversion. Organ function, pregnancy, age, smoking status, infection, and treatment adherence also influence actual exposure and response.
Therefore, clinicians interpret genetic results in conjunction with medication lists, dosages, and therapeutic goals. Genetic information is not a blank check that overrides other clinical data; rather, it represents one layer of evidence that reduces specific uncertainties.
Points of Confusion
- A reported pharmacogenetic association does not immediately translate into a clinical recommendation.
- Raw genotype data from consumer genetic tests are not equivalent to clinically validated pharmacogenomic reports.
- The phenotype associated with a single gene does not apply uniformly to all drugs.
- Recommendations in guidelines differ from national regulatory approvals, insurance policies, and healthcare institution protocols.
Limitations
The evidence may be subject to bias depending on ancestry composition, study design, and the type of clinical outcomes. Rare alleles and complex structural variants may not be included in the assay, and allele definitions and guidelines are subject to updates. A robust report should present not only definitive results but also undetected regions, ambiguous calls, the versions used, and their applicability.
Pharmacogenetic results do not constitute a diagnosis nor an independent prescription order. Actual medication adjustments and management of adverse reactions fall within the scope of current professional guidelines and the clinical judgment of the treating physician.
Reading in Context
The implementation of this workflow by automated pharmacogenomic reports is linked to the PharmCAT Concept. The principle of integrating multiple lines of evidence for the clinical interpretation of variants continues into the Functional Assays and Variant Interpretation Concept.